The Production of Reactive Oxygen Species Is a Universal Action Mechanism of Amphotericin B against Pathogenic Yeasts and Contributes to the Fungicidal Effect of This Drug

Molecular Identification and Antifungal Susceptibility of Yeast Isolates Causing Fungemia Collected in a Population-Based Study in Spain in 2010 and 2011

(2013) Jesús Guinea et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Candida tropicalis Antifungal Cross-Resistance Is Related to Different Azole Target (Erg11p) Modifications

(2013) A. Forastiero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Insight into Amphotericin B Resistance in Aspergillus terreus

(2013) Gerhard Blum et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of rare invasive yeast infections

(2013) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

Potentiation of Antibiofilm Activity of Amphotericin B by Superoxide Dismutase Inhibition

(2013) Katrijn De Brucker et al.   Oxidative Medicine and Cellular Longevity

Fungicidal Drugs Induce a Common Oxidative-Damage Cellular Death Pathway

(2013) Peter Belenky et al.   Cell Reports

Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B

(2013) Benjamin Matteson Vincent et al.   PLOS BIOLOGY

Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants

(2012) Nuo Sun et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

(2012) O.A. Cornely et al.   CLINICAL MICROBIOLOGY AND INFECTION

EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*

(2012) Maiken C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

(2012) W.W. Hope et al.   CLINICAL MICROBIOLOGY AND INFECTION

In vitro and in vivo role of heat shock protein 90 in Amphotericin B resistance of Aspergillus terreus

(2012) G. Blum et al.   CLINICAL MICROBIOLOGY AND INFECTION

Physiological Roles of Mitochondrial Reactive Oxygen Species

(2012) Laura A. Sena et al.   MOLECULAR CELL

Amphotericin primarily kills yeast by simply binding ergosterol

(2012) K. C. Gray et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug

(2012) Ana C. Mesa-Arango et al.   Frontiers in Microbiology

Mitochondrial complex I: A central regulator of the aging process

(2011) Rhoda Stefanatos et al.   CELL CYCLE

Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice?

(2011) Anna Turkova et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Recomendaciones sobre el tratamiento de la enfermedad fúngica invasiva por Aspergillus spp. y otros hongos filamentosos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011

(2011) Jesús Fortún et al.   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst

(2011) Fernanda Sangalli-Leite et al.   MICROBES AND INFECTION

Changes in the Proteome of Candida albicans in Response to Azole, Polyene, and Echinocandin Antifungal Agents

(2010) C. F. Hoehamer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Heteroresistance of Cryptococcus gattii to Fluconazole

(2010) A. Varma et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synthesis and biological evaluation of amphotericin B derivatives

(2010) Astrid A. Volmer et al.   NATURAL PRODUCT REPORTS

Liposomal Amphotericin B

(2009) Marit D. Moen et al.   DRUGS

The Hog1 MAP kinase controls respiratory metabolism in the fungal pathogen Candida albicans

(2009) Rebeca Alonso-Monge et al.   MICROBIOLOGY-SGM

Amphotericin B: side effects and toxicity

(2009) Rafael Laniado-Laborín et al.   REVISTA IBEROAMERICANA DE MICOLOGIA

Synthesis and Biological Studies of 35-Deoxy Amphotericin B Methyl Ester

(2008) Alex M. Szpilman et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Potential Basis for Amphotericin B Resistance in Aspergillus terreus

(2008) G. Blum et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Immunocompromised Hosts: Immunopharmacology of Modern Antifungals

(2008) R. Ben‐Ami et al.   CLINICAL INFECTIOUS DISEASES

EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

(2008) J.L. Rodriguez-Tudela et al.   CLINICAL MICROBIOLOGY AND INFECTION

Pharmacotherapy of yeast infections

(2008) Alicia Gómez-López et al.   EXPERT OPINION ON PHARMACOTHERAPY

Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients

(2008) Ioanna Filioti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Renal impairment and Amphotericin B formulations in patients with invasive fungal infections

(2008) Faouzi Saliba et al.   MEDICAL MYCOLOGY

Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi

(2008) B. G. Oliver et al.   MICROBIOLOGY-SGM

Amphotericin B Formulations and Drug Targeting

(2007) J.J. Torrado et al.   JOURNAL OF PHARMACEUTICAL SCIENCES